Executives of Hims & Hers ... imitation semaglutide was nearing an end. The FDA in October said the shortage of Eli Lilly’s weight-loss drug tirzepatide was over and directed compounding ...

In May 2024, Hims & Hers stock surged after it had been allowed to offer a compounded semaglutide due to a semaglutide shortage. But once the U.S. Food and Drug Administration (FDA) declared that ...

Hims & Hers Health announced today that it has entered into “a long-term collaboration” with Danish drugmaker Novo Nordisk to offer its popular weight-loss drug Wegovy to its users through the ...

A US judge has rejected efforts by a compounded drugs industry group to keep making an alternative version of Novo Nordisk’s popular drug semaglutide ... such as Hims & Hers have surged in ...

Hims & Hers and other telehealth companies took a hit when the Food and Drug Administration (FDA) announced that semaglutide was no longer in short supply, making it ineligible for compounding.

Earlier this year, the Danish pharma traded barbs with telehealth provider Hims & Hers over the latter’s practice of selling compounded versions of semaglutide, the drug better known as Novo’s ...

Hims & Hers stock has dropped over 60% from its peak due to concerns about its GLP-1 business. Read why I think HIMS stock is ...

Hims & Hers started prescribing compounded semaglutide, the active ingredient in Novo Nordisk's diabetes drug Ozempic and Wegovy, in May of 2024. The company has largely had to stop offering the ...

And it wasn’t just Hims & Hers offering compounded ... approved drug is not appropriate for a patient, such as in the case of an allergy. Although there had been a shortage of semaglutide ...